In recent months, the U.S. Department of Justice and Federal Trade Commission have started to take action to rein in antitrust behavior, including banning noncompete agreements in the for-profit sector and establishing a taskforce on healthcare monopolies.
HHS Final Rule Reinstates ACA Nondiscrimination Provisions
Effective July 5, discrimination based on race, color, national origin, sex, age and disability by healthcare programs receiving federal assistance is once again prohibited. The application of Section 1557 to all HHS health programs and activities and state and federally facilitated exchanges, which had been weakened by the Trump administration, has been reinstated.
What Rheumatologists Need to Know About Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an acquired thromboinflammatory disease that can have severe, sometimes catastrophic, effects on patients and their families. Our modern understanding of APS began to emerge in the early 1980s. At that point, it was defined as a condition characterized by thrombotic episodes and/or pregnancy complications in the presence of antiphospholipid antibodies (aPL).1…
FDA Approves Tocilizumab Biosimilar; Plus New Lupus Drug in Early Trials
The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.
How to Effectively Diagnose & Treat Macrophage Activation Syndrome
“As a resident, [I] felt pretty terrible when [we had] a very sick child and the teams [couldn’t] agree on what to do,” said Lauren Henderson, MD, MMS, on an episode of ACR on Air. She discussed the importance of collaboration across specialties in the identification and treatment of macrophage activation syndrome (MAS).
Calprotectin Shows Promise as APS Thrombocytopenia Biomarker
Hoy et al. sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of patients with primary antiphospholipid syndrome (APS) and those with antiphospholipid antibodies. Calprotectin levels were higher in patients with primary APS and those with antiphospholipid antibodies than in healthy controls. These data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS-related thrombocytopenia.
New Indications Possible for Bimekizumab-bkzx
The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
ACR Delegation to Lead Several Resolutions at June AMA House of Delegates Meeting
The ACR will lead five other specialty societies on a resolution supporting pediatric specialty care and will co-lead resolutions addressing Medicare Advantage Part B drug coverage, white bagging mandates, state prescription drug affordability boards and impacts of alternative funding programs on access to care.
A Fellow’s Experience at Advocacy 101
Rheumatology fellow Audrey Liu, MD, describes the excitement and empowerment of seeing first-hand the real-world impact of advocating for policies that support providers and patients.
ACR Hill Day Participants Urge Congress to Reform Medicare Reimbursement
On May 6–7, nearly 100 rheumatologists and rheumatology professionals converged in Washington, D.C., for the ACR’s annual Advocacy Leadership Conference and 137 meetings on Capitol Hill. You can help extend the efforts of these advocates and amplify their impact by contacting your lawmakers via the Legislative Action Center.
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 814
- Next Page »